EX-99.1 2 d924981dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

ASX/Media Release     

Immutep’s Phase II TACTI-002 Study

Reports Encouraging Data at SITC

 

 

Overall Response Rates (ORR) in 1st line NSCLC and 2nd line HNSCC continue to be very favourable

 

 

5 patients with a Complete Response (disappearance of all lesions): 2 patients in 1st line NSCLC and 3 patients in 2nd line HNSCC

 

 

Encouraging efficacy for low PD-L1 expressing patients who do not typically respond to immune checkpoint (PD-L1) therapy

 

 

Partial response and long lasting stabilization of disease as well as favourable Overall Survival (OS) in PD-1/PD-L1 resistant/refractory patients leading to a favorable DMC recommendation to open Stage 2 of 2nd line NSCLC of the trial

SYDNEY, AUSTRALIA – 10 November 2020 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces encouraging new interim data from its ongoing Phase II TACTI-002 study evaluating the combination of eftilagimod alpha (“efti” or “IMP321”) with MSD’s KEYTRUDA® (pembrolizumab).

The data was presented by TACTI-002 Principal Investigator, Dr Matthew Krebs of the Christie NHS Foundation Trust in Manchester, UK at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary 2020 Annual Meeting as part of a late breaker poster presentation and poster walk for highly scored abstracts.

The poster is also available on Immutep’s website: www.immutep.com

Principal investigator, Dr Matthew Krebs, said: “In first-line NSCLC and second-line HNSCC we are seeing very encouraging results compared to historical studies where pembrolizumab has been given as monotherapy in comparable patient groups. These results highlight the potential therapeutic benefit of adding efti to the checkpoint inhibitor pembrolizumab, together with an excellent safety profile. The data strongly support further evaluation of the combination in both lung and head and neck cancers.”

Immutep CSO and CMO, Dr Frederic Triebel said: “We are very encouraged by the number of lung cancer and head and neck cancer patients responding to efti in combination with pembrolizumab, including many patients that wouldn’t typically respond to immune checkpoint therapy. We have presented here more mature data from Stage 1 of Parts A and C of the trial, along with first data from Stage 2 of Parts A and C. We have also presented first data from Part B of the trial where patients are PD-1 resistant (confirmed by two confirmatory scans).

The results from this trial, and our other trials, continue to support our hypothesis that the combination of our lead product candidiate, efti, with a PD-1 inhibtor such as pembrolizumab should result in a meaningful benefit to patients across various cancers. These results are supportive of further late stage clinical development.”

 

Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000

ABN: 90 009 237 889


LOGO

 

Table 1TACTI-002 Interim Results (data cut-off date: 8 October 2020)

 

    

Part A

1st line NSCLC

    

Part B

2nd line NSCLC

    

Part C

2nd line HNSCC

 
Tumour response - iBOR per iRECIST   

Stages 1 & 2

N (%)

Total (N=36)

    

Stage 1

N (%)

Total (N=23)

    

Stage 1 & 2

N (%)

Total (N=28)

 

Complete Response (iCR)

     2 (5.6)        0 (0)        3 (10.7)  

Partial Response (iPR)

     11 (30.6)        1 (4.4)        7 (25.0)  

Stable Disease (iSD)

     11 (30.6)        7 (30.4)        3 (10.7)  

Progressive Disease (iPD)

     9 (25.0)        14 (60.9)        10 (35.7)  

Not evaluable

     3 (8.3)        1 (4.4)        5 (17.9)  

Disease Control Rate (DCR)

     24 (66.7)        8 (34.8)        13 (46.4)  

Objective Response Rate (iORR) ITT*

     13 (36.1)        1 (4.4)        10 (35.7)  

Objective Response Rate in eval. pts

     13 (39.4)        1 (4.5)        10 (43.5)  

 

*

Intention-to-treat (ITT) analysis of the results of an experiment is based on the initial treatment assignment and not on the treatment eventually received. ITT analysis is intended to avoid various misleading artifacts that can arise in intervention research such as non-random attrition of participants from the study or crossover.

2nd line HNSCC - Part C

Stages 1 and 2 combined results commentary:

 

 

Overall response rate stays consistent with approximately 36% (approximately 44% in evaluable patients) and is more than double compared to KEYNOTE studies (ORR ~15%)1,2 in a comparable patient population

 

 

Durable and deep responses including 3 patients with a Complete Response

 

 

Responses in low PD-L1 status patients which do not typically respond to PD-L1 therapy

 

 

All patients with a response except one still under therapy g in total 10/28 patients still under therapy at data cut-off date (7 patients for 6+ months) g PFS and OS trend favorably

Conclusion: Data presented for HNSCC is very robust and form an excellent basis for late stage clinical development in this indication.

1st line NSCLC - Part A

Stages 1 and 2 combined results commentary:

 

 

Patients recruited into Stages 1 and 2 represent slightly different patient populations

 

 

13 patients with responses (ORR ITT: approximately 36% and in evaluable patients: approximately 39%) including 2 patients with a Complete Response

 

 

22/36 (61%) of patients had a target lesion decrease

 

 

Responses were reported in all PD-L1 subgroups:

 

   

ORR for patients in the ³ 1% PD-L1 subgroup was 44% (11/25). Compares favourably to ORR of ~27% from a comparable patient population receiving pembrolizumab alone3,4.

 

   

ORR for patients in the < 50% PD-L1 subgroup was 31.6% (6/19). Compares favourably to ORR of < 20% from a comparable patient population receiving pembrolizumab alone, signaling encouraging efficacy for low PD-L1 expressing patients which do not typically respond to immune checkpoint (PD-L1) therapy.

 

 

11 patients were still under therapy at data cut-off date thereof including 6 patients for 12+ months g PFS trends favorably

 

1 

Seiwert T Y et al, 2016; Lancet 17: 956-965 (KN-012)

2 

Cohen E, et al. Lancet 2019; 393: 156-167 (KN-040)

3 

KEYNOTE trial: Mok T, et al. Lancet 2019; 393: 1819-1830 (KN-042)

4 

KEYNOTE trial: Reck M, et al. N Engl J Med. 2016; 375:1823-1833 (KN-024)

 

Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000

ABN: 90 009 237 889


LOGO

 

The patient characteristics of Stages 1 and 2 of Part A of TACTI-002 are shown in Table 2. The median age of patients in Stage 2 is almost 10 years older than patients in Stage 1. Furthermore, 84% of patients in Stage 2 had an ECOG status of 1 meaning that they are more impacted from deteriorating health, whereas only 29.4% of patients from Stage 1 had an ECOG status of 1.

Table 2TACTI-002 Part A (Stages 1 and 2) Patient Characteristics (excerpt)

 

Baseline Characteristics   

Stage 1 (N=17)

N (%)

    

Stage 2 (N=19)

N (%)

    

Stage 1+2 (N=36)

N (%)

 

Median age, years (range)

     65 (53-76)        74 (60-84)        68.5 (53-84)  

ECOG 0

     12 (70.6)        3 (16)        15 (41.7)  

ECOG 1

     5 (29.4)        16 (84)        21 (58.3)  

Squamous (SQ)

     10 (58.8)        5 (26)        15 (41.7)  

Non-squamous (NSQ)

     7 (41.2)        14 (73)        21 (58.3)  

The percentage of patients with progressive disease was similar in both stages (refer to Table 3 below) suggesting a similar overall clinical benefit from the combination therapy in both sets of patients.

Notably, there were more patients in Stage 2 with radiological assessment not reaching the arbitrary 30% bar that were then categorized as having “stable disease” rather than a “partial response”, possibly due to worse initial prognostic characteristics (i.e. older age and worse ECOG status) of those patients.

Table 3TACTI-002 Part A (Stages 1 and 2) Interim Results

 

Tumour response (iRECIST)   

Stage 1 (N=17)

N (%)

    

Stage 2 (N=19)

N (%)

    

Stage 1+2 (N=36)

N (%)

 

Complete Response

     1 (5.9)        1 (5.3)        2 (5.6)  

Partial Response

     8 (47.1)        3 (15.8)        11 (30.6)  

Stable Disease

     4 (23.5)        7 (36.8)        11 (30.6)  

Progressive Disease

     4 (23.5)        5 (26.3)        9 (25.0)  

Not Evaluable

     0 (0)        3 (15.8)        3 (8.3)  

Overall Response Rate ITT

 

     13 (36.1)  

[95% Cl interval]

 

     [20.8-53.8]

Overall Response Rate (evaluable patients only)

 

     13/33 (39.4)  

Disease Control Rate

 

     24 (66.7)  

 

Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000

ABN: 90 009 237 889


LOGO

 

Conclusion: Data presented for 1st line NSCLC are favorable and form an excellent basis for further clinical development in this indication.

2nd line NSCLC - Part B

Stage 1 results commentary:

 

 

Very difficult to treat patient population with:

 

   

confirmed progression (2 consecutive scans) on PD-1/PD-L1 containing therapy

 

   

85% of patients have PD-L1 of < 50% g PD-L1 low expressors predominant

 

   

best response of PD-1/PD-L1 containing therapy was SD/PD in 61% of patients g potential primary resistance

 

   

majority (61%) received chemotherapy plus PD-1/PD-L1 in 1st line setting

 

 

1 confirmed partial response (6+ months; patient still under therapy)

 

 

4 patients (17.4%) stable or responding for 6+ months and 2 additional patients ongoing at 2+ months

 

 

³ 50% still alive at 12 month landmark which compares favorably to standard of care chemotherapy alone (where only the 6 month landmark is expected to be reached by 50% of patients)5.

Conclusion: Data presented for 2nd line PD-1/PD-L1 resistant NSCLC looks very encouraging especially if compared to alternative treatment options. Based on this data, the DMC confirmed a positive risk-benefit ratio for Part B and recommended the opening of Stage 2 of this part.

Safety

The combination treatment continues to be safe and well tolerated with no new safety signals reported so far.

TACTI-002 Recruitment Update

Recruitment into the TACTI-002 trial continues to progress well and is ongoing for Stage 2 of Part C. Part B has received a favorable DMC recommendation to open Stage 2 for recruitment. In total, 94 patients out of up to 109 are enrolled across 12 clinical sites in Australia, Europe, the UK and US.

Recruitment details for each part of the trial are shown in Table 4.

Table 4TACTI-002 Recruitment (as at 2 November 2020)

 

    

Stage 1 (N)

Actual / target

  

Stage 2 (N)

Actual / target

  

Recruitment

Status

Part A (1st line NSCLC)

   17/17    19/19    COMPLETE

Part B (2nd line NSCLC)

   23/23    0/13    NOT YET OPENED

Part C (2nd line HNSCC)

   18/18    17/19    ONGOING

Next Results

Immutep expects to report more mature data from TACTI-002 in the first half of CY 2021.

About the TACT-002 Trial

TACTI-002 (Two ACTive Immunotherapies) is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada). The study is evaluating the combination of efti with MSD’s KEYTRUDA® (pembrolizumab) in up to 109 patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.

 

5 

Brahmer et al.: N Engl J Med 2015; 373:123-135 (CM-017)

 

Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000

ABN: 90 009 237 889


LOGO

 

More information about the trial can be found on Immutep’s website or on ClinicalTrials.gov (Identifier: NCT03625323).

About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.

Further information can be found on the Company’s website www.immutep.com or by contacting:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS

+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:

Tim McCarthy, LifeSci Advisors

+1 (212) 915.2564; tim@lifesciadvisors.com

This announcement was authorised for release by the Board of Immutep Limited.

 

Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000

ABN: 90 009 237 889